Dupixent Eczema Misdiagnosis and CTCL Lymphoma Risk

You took Dupixent for eczema. The itching calmed down for a while, then the patches came back worse, or they never fully cleared.
Months later, a biopsy came back with a word you never expected. Cancer.

At least 15 patients had their claims moved into one federal Dupixent lawsuit in June 2026, and more have filed since. Each person tells a similar story, eczema treatment first and a cutaneous T-cell lymphoma diagnosis later.

You don’t need to have all the answers to take the next step. The timing of your diagnosis can affect a legal claim, and that’s worth understanding before you decide anything.

What Early Cutaneous T-Cell Lymphoma Looks Like on the Skin

Most itchy, scaly rashes are exactly what they seem. Cancer is a rare cause. Rare doesn’t mean never, though, and that small chance is why doctors sometimes biopsy stubborn eczema.

Cutaneous T-cell lymphoma, or CTCL, is a rare cancer of the skin’s T-cells. Its most common form is mycosis fungoides. In its earliest stage, it can look almost identical to eczema or psoriasis, and that resemblance is what makes it so easy to miss.

The National Cancer Institute describes how it usually starts. A scaly, red rash shows up in places that normally stay covered, like the hips, buttocks, or trunk. It can linger for months or even years.

Early on it may be nothing more than a thin, reddened patch that reads as ordinary eczema. Only later do raised plaques or skin tumors appear.

When a Rash Is Worth a Second Look

Diagnosis often takes more than one try. Early CTCL can hide from a single biopsy, so doctors sometimes need repeat samples and lab tests that look for abnormal T-cell clones.

A slow workup like that is normal medicine. It turns into a legal question only when something made the delay longer than it had to be.

How Dupixent Can Mask an Underlying T-Cell Problem

Dupixent (the brand name for dupilumab) works by blocking two immune signals, called IL-4 and IL-13. Those signals drive much of the inflammation and itch behind eczema. Quiet them, and the skin often calms down.

The problem is what those same signals normally do. IL-4 and IL-13 are part of how your immune system spots and reacts to abnormal T-cells. Turn the inflammation down, and the skin can look calmer even while abnormal cells keep growing underneath.

That’s why some patients watch the rash fade for a few months, then return worse than before. The eczema treatment seemed to be working, so no one ordered a biopsy. Meanwhile the real problem had time to advance.

Masking or Causing? What the Science and the Lawsuits Say

There are two main theories, and they lead to different arguments in court.

The first is unmasking. Under this view, the cancer was already there, misread as eczema, and Dupixent let it show itself and advance while everyone treated the wrong illness.

One finding supports that idea. Studies so far connect Dupixent to the one lymphoma that mimics eczema, while other blood cancers don’t show the same link.

The second theory is acceleration. Some experts and plaintiffs argue the drug’s effect on those immune signals can speed up a cancer that has already started. Regeneron and Sanofi, the companies behind Dupixent, dispute the cause claim and the acceleration claim.

No court has decided who’s right. In June 2026, a federal panel gathered the lawsuits into one proceeding, MDL No. 3180, in the District of New Jersey before Judge Zahid Quraishi.

An MDL isn’t a class action, and it isn’t a verdict. It groups similar lawsuits so a court can rule on the questions they share. Central among them are the drug’s role in the cancer, what the companies knew, and when they knew it.

Robert Baker, who founded Baker Legal Team, spent his early career as a prosecutor in Kings County, New York. Building a causation case is close to building a criminal one. You line up the timeline, then show what the other side knew and when.

Here that means the medical record on one side and the company’s own knowledge of the risk on the other.

Why a Late Diagnosis Can Become a Legal Claim

These cases turn on timing. A clear warning might have caught the cancer sooner.

The legal theory is called failure to warn. If Dupixent’s label didn’t warn doctors and patients about a possible CTCL risk, they had no reason to order an early biopsy. The same is true if it never flagged how the drug can hide the disease.

So doctors kept treating eczema, and the cancer moved to a later stage.

Why does timing carry so much weight here? Stage changes the whole picture with this disease. Early mycosis fungoides is often managed for years, but once it advances, treatment gets harder and the outlook changes.

The harm in these claims is that lost time, the months or years when a different label might have changed the care.

What to Gather Before You Call a Lawyer

You don’t need a perfect file to make the first call. Still, a few records make it much easier to see whether you have a claim, and they protect you if memories fade later.

Can’t find all of it? A lawyer can request most medical records for you. Bring what you have, and let the questions guide the rest.

Common Questions About Dupixent and T-Cell Lymphoma Claims

Past results do not guarantee future outcomes. Nothing here is medical or legal advice, and reading it or submitting the form does not create an attorney-client relationship.